- Home
- SNDR vs DFTX Comparison
SNDR vs DFTX Comparison
Compare SNDR & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNDR | DFTX |
|---|---|---|
| Founded | 1935 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.9B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SNDR | DFTX |
|---|---|---|
| Price | $31.25 | $36.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 19 |
| Target Price | $35.86 | ★ $72.33 |
| AVG Volume (30 Days) | 737.1K | ★ 2.0M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $5,674,300,000.00 | N/A |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | $6.47 | N/A |
| P/E Ratio | $77.25 | ★ N/A |
| Revenue Growth | ★ 7.25 | N/A |
| 52 Week Low | $20.11 | $14.62 |
| 52 Week High | $39.27 | $49.70 |
Technical Indicators
Market Signals| Indicator | SNDR | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 49.38 |
| Support Level | $30.52 | $32.84 |
| Resistance Level | $33.27 | $38.04 |
| Average True Range (ATR) | 0.89 | 1.70 |
| MACD | 0.04 | 0.22 |
| Stochastic Oscillator | 40.54 | 67.39 |
Price Performance
Historical ComparisonAbout SNDR Schneider National Inc.
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, LTL carriers, railroads, ocean carriers, airlines to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload, Intermodal, Logistics and other. It generates maximum revenue from the Truckload segment.
About DFTX Definium Therapeutics Inc. Common Shares
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.